Skip to main content

Table 2 Changes operated on clinical and laboratory parameters after anti-TNFα/DMARDs treatment in responder and non-responder RA patients

From: Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFα

  Responders (N = 85) Non-responders (N = 10)
  Before anti-TNF treatment After anti-TNF treatment P Before anti-TNF treatment After anti-TNF treatment P
Clinical assessments       
TJC 15.9 ± 4.8 5.1 ± 2.2 0.000 15.6 ± 5.1 8.5 ± 2.9 0.005
SJC 11.7 ± 3.9 2.9 ± 1.8 0.000 11.6 ± 4.9 5.1 ± 2.7 0.005
DAS28 5.8 ± 0.6 3.3 ± 0.7 0.000 5.5 ± 0.7 4.3 ± 0.6 0.005
SDAI 36.3 ± 11.4 2.9 ± 6.8 0.000 39.2 ± 11.8 5.7 ± 12.1 0.005
HAQ 2.1 ± 0.3 1 ± 0.4 0.000 2.1 ± 0.3 1 ± 0.3 0.008
Serological assessments       
ESR (mm/h) 56.4 ± 17.2 27.9 ± 18.5 0.000 51.4 ± 11.9 37.6 ± 19.3 ns
CRP (mg/L) 3.9 ± 2.1 1.5 ± 1.2 0.000 2.2 ± 0.8 2.5 ± 0.9 ns
RF (U/L) 155.2 ± 288.3 85.4 ± 241 0.000 61.2 ± 84.3 20.8 ± 39.9 0.027
IL-6 (pg/mL) 9.4 ± 46.7 1.4 ± 6.8 0.000 2.1 ± 5.6 0 ns
TNF (pg/mL) 14.9 ± 28.8 5.7 ± 6.1 0.038 4.1 ± 4.5 4.7 ± 5.1 ns
sTNFRII (pg/mL) 1.5 ± 0.9 1.5 ± 0.7 ns 1.3 ± 0.4 1.5 ± 0.7 ns
MCP-1 (pg/mL) 1174.8 ± 1615.4 1216.4 ± 1655.4 ns 740 ± 504.6 678.6 ± 221.8 ns
VEGF (pg/mL) 1107.7 ± 1360.9 830.3 ± 570.1 ns 796.7 ± 462.7 1077.9 ± 711.6 ns
IL23 (pg/mL) 115 ± 235.5 76.8 ± 132.9 ns 41.2 ± 30.5 223.5 ± 424.8 ns
IL22 (pg/mL) 46.3 ± 112 17.2 ± 29.2 ns 8.4 ± 8.1 104.9 ± 193.3 ns
IL17 (pg/mL) 4.8 ± 8.5 2.1 ± 2.1 0.024 11.9 ± 19.1 1.4 ± 1.4 ns
IL4 (pg/mL) 22.8 ± 17.6 14.9 ± 16.2 ns 4.2 ± 6 12.8 ± 18.2 ns
  1. TNFα, tumor necrosis factor alpha; DMARDS, disease-modifying antirheumatic drugs; RA, rheumatoid arthritis; T1 baseline; T2 at 6 months; TJC, tender joint count; SJC, swollen joint count; DAS28, disease activity score; SDAI, simplified disease activity index; HAQ, health assessment questionnaire; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; RF, rheumatoid factor; IL-6, interleukin 6; TNF, tumor necrosis factor; sTNFRII, soluble tumor necrosis factor receptor type II; MCP-1, monocyte chemoattractant protein 1; VEGF, vascular endothelial growth factor; IL-23, interleukin 23; IL-22, interleukin 22; IL-17, interleukin 17; IL-4, interleukin 4.